Download PDF
Planta Med 2011; 77(2): 196-204
DOI: 10.1055/s-0030-1250161
Biological Screening
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Inhibition of Advanced Glycation End Product Formation by Medicinal Plant Extracts Correlates with Phenolic Metabolites and Antioxidant Activity

Cory S. Harris1 , 2 , 3 , Louis-Philippe Beaulieu1 , 3 , Marie-Hélène Fraser3 , 4 , 5 , Kristina L. McIntyre1 , 3 , Patrick L. Owen3 , 7 , Louis C. Martineau3 , 6 , Alain Cuerrier3 , 4 , Timothy Johns3 , 5 , 7 , Pierre S. Haddad3 , 6 , Steffany A.L. Bennett2 , 3 , John T. Arnason1 , 3
  • 1Centre for Research in Biopharmaceuticals and Biotechnology, Department of Biology, University of Ottawa, Ottawa, ON, Canada
  • 2Neural Regeneration Laboratory, Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada
  • 3Canadian Institute of Health Research Team in Aboriginal Anti-diabetic Medicines, Montréal, QC, Canada
  • 4Institut de recherche en biologie végétale et le Jardin botanique de Montréal, Montréal, QC, Canada
  • 5Department of Plant Science, McGill University, Ste. Anne-de-Bellevue, Canada
  • 6Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology, Université de Montréal and Montreal Diabetes Research Center, Montréal, QC, Canada
  • 7School of Dietetics and Human Nutrition, McGill University, Ste. Anne-de-Bellevue, QC, Canada
Further Information

Publication History

received April 9, 2010 revised June 22, 2010

accepted June 28, 2010

Publication Date:
17 August 2010 (online)

    Permissions and Reprints

Abstract

Nonenzymatic formation of advanced glycation end products (AGEs) is accelerated under hyperglycemic conditions characteristic of type 2 diabetes mellitus and contributes to the development of vascular complications. As such, inhibition of AGE formation represents a potential therapeutic target for the prevention and treatment of diabetic complications. In the present study, ethanolic extracts of 17 medicinal plants were assessed for inhibitory effects on in vitro AGE formation through fluorometric and immunochemical detection of fluorescent AGEs and N ε-(carboxymethyl)lysine adducts of albumin (CML‐BSA), respectively. Most extracts inhibited fluorescent AGE formation with IC50 values ranging from 0.4 to 38.6 µg/mL and all extracts reduced CML‐BSA formation but to differing degrees. Results obtained through both methods were highly correlated. Antiglycation activities were positively correlated with total phenolic content, free radical scavenging activity and reduction in malonyldiadehyde levels following oxidation of low-density lipoprotein, but negatively correlated with lag time to formation of conjugated dienes. Together, these results provide evidence that antioxidant phenolic metabolites mediate the antiglycation activity of our medicinal plant collection, a relationship that likely extends to other medicinal and food plants.

Key words

advanced glycation end products - diabetes - diabetic complications - plant phenolics - oxidative stress - antioxidants

References

  • 1 Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world.  Br J Nurs. 2007;  16 1002-1007
    CrossrefPubMedGoogle Scholar
  • 2 Ulrich P, Cerami A. Protein glycation, diabetes, and aging.  Recent Prog Horm Res. 2001;  56 1-21
    CrossrefPubMedGoogle Scholar
  • 3 Ramasamy R. Glycation and RAGE: Common links in the pathogenesis of microvascular and macrovascular complications of diabetes.  Can J Diabetes. 2006;  30 422-429
    PubMedGoogle Scholar
  • 4 Bierhaus A, Humpert P M, Morcos M, Wendt T, Chavakis T, Arnold B, Stern D M, Nawroth P P. Understanding RAGE, the receptor for advanced glycation end products.  J Mol Med. 2005;  83 876-886
    CrossrefPubMedGoogle Scholar
  • 5 Young T K, Reading J, Elias B, O'Neil J D. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress.  CMAJ. 2000;  163 561-566
    PubMedGoogle Scholar
  • 6 Assembly of First Nations .A First Nations Diabetes Report Card. Part 1: Marking a path to community wellness. Ottawa, ON; Assembly of First Nations 2006: 31
    PubMedGoogle Scholar
  • 7 Booth G L, Hux J E, Fang J, Chan B T. Time trends and geographic disparities in acute complications of diabetes in Ontario, Canada.  Diabetes Care. 2005;  28 1045-1050
    CrossrefPubMedGoogle Scholar
  • 8 Young T K, Reading J, Elias B, O'Neil J D. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress.  CMAJ. 2000;  163 561-566
    PubMedGoogle Scholar
  • 9 Yu C H, Zinman B. Type 2 diabetes and impaired glucose tolerance in aboriginal populations: a global perspective.  Diabetes Res Clin Pract. 2007;  78 159-170
    CrossrefPubMedGoogle Scholar
  • 10 Wu C H, Yen G C. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts.  J Agric Food Chem. 2005;  53 3167-3173
    CrossrefPubMedGoogle Scholar
  • 11 Fraser M-H, Cuerrier A, Haddad P, Arnason J T, Owen P, Johns T. Medicinal plants of Cree communities (Québec, Canada): antioxidant activity of plants used to treat type 2 diabetes symptoms.  Can J Physiol Pharmacol. 2007;  85 1200-1214
    CrossrefPubMedGoogle Scholar
  • 12 Spoor D C, Martineau L C, Leduc C, Benhaddou-Andaloussi A, Meddah B, Harris C, Burt A, Fraser M H, Coonishish J, Joly E, Cuerrier A, Bennett S A, Johns T, Prentki M, Arnason J T, Haddad P S. Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential.  Can J Physiol Pharmacol. 2006;  84 847-858
    CrossrefPubMedGoogle Scholar
  • 13 Leduc C, Coonishish J, Haddad P, Cuerrier A. Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative ethnobotany.  J Ethnopharmacol. 2006;  105 55-63
    CrossrefPubMedGoogle Scholar
  • 14 Harbilas D, Martineau L C, Harris C S, Adeyiwola-Spoor D C A, Saleem A, Lambert J, Caves D, Johns T, Prentki M, Cuerrier A, Arnason J T, Bennett S A L, Haddad P S. Evaluation of the anti-diabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II.  Can J Physiol Pharmacol. 2009;  87 479-492
    CrossrefPubMedGoogle Scholar
  • 15 Beaulieu L P, Harris C S, Saleem A, Cuerrier A, Haddad P S, Martineau L C, Bennett S A, Arnason J T. Inhibitory effect of the Cree traditional medicine wiishichimanaanh (Vaccinium vitis-idaea) on advanced glycation endproduct formation: identification of active principles.  Phytother Res. 2009;  24 741-747
    PubMedGoogle Scholar
  • 16 Suzuki R, Okada Y, Okuyama T. Two flavone C-glycosides from the style of Zea mays with glycation inhibitory activity.  J Nat Prod. 2003;  66 564-565
    CrossrefPubMedGoogle Scholar
  • 17 Singleton V L, Rossi Jr. J A. Colorimetry of total phenolics with phosphomolybdic-phosphotungistic acid reagents.  Am J Enol Vitic. 1965;  16 144-158
    PubMedGoogle Scholar
  • 18 Gillespie K M, Chae J M, Ainsworth E A. Rapid measurement of total antioxidant capacity in plants.  Nat Protoc. 2007;  2 867-870
    CrossrefPubMedGoogle Scholar
  • 19 Cotelle N, Bernier J L, Catteau J P, Pommery J, Wallet J C, Gaydou E M. Antioxidant properties of hydroxy-flavones.  Free Radic Biol Med. 1996;  20 35-43
    CrossrefPubMedGoogle Scholar
  • 20 Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein.  Free Radic Res Commun. 1989;  6 67-75
    CrossrefPubMedGoogle Scholar
  • 21 Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study.  Prostaglandins Leukot Essent Fatty Acids. 2000;  63 177-186
    CrossrefPubMedGoogle Scholar
  • 22 Harris C S, Lambert J, Saleem A, Coonishish J, Martineau L C, Cuerrier A, Haddad P S, Arnason J T, Bennett S A L. Anti-diabetic activity of extracts from needle, bark and cone of Picea glauca: organ specific protection from glucose toxicity and glucose deprivation.  Pharm Biol. 2008;  46 126-134
    CrossrefPubMedGoogle Scholar
  • 23 Martineau L C, Muhammad A, Saleem A, Herve J, Harris C S, Arnason J T, Haddad P S. Anti-adipogenic activities of Alnus incana and Populus balsamifera bark extracts, part II: bioassay-guided identification of actives salicortin and oregonin.  Planta Med. 2010;  DOI: 10.1055/s-0029-1240991
    PubMedGoogle Scholar
  • 24 Saleem A, Harris C S, Asim M, Cuerrier A, Martineau L, Haddad P S, Arnason J T. A RP-HPLC-DAD-APCI/MSD method for the characterisation of medicinal Ericaceae used by the Eeyou Istchee Cree First Nations.  Phytochem Anal. 2010;  DOI: 10.1002/pca.1203
    CrossrefPubMedGoogle Scholar
  • 25 Munch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease.  Brain Res Brain Res Rev. 1997;  23 134-143
    CrossrefPubMedGoogle Scholar
  • 26 Kilhovd B K, Juutilainen A, Lehto S, Ronnemaa T, Torjesen P A, Hanssen K F, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study.  Diabetologia. 2007;  50 1409-1417
    CrossrefPubMedGoogle Scholar
  • 27 Peng X, Cheng K W, Ma J, Chen B, Ho C T, Lo C, Chen F, Wang M. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts.  J Agric Food Chem. 2008;  56 1907-1911
    CrossrefPubMedGoogle Scholar
  • 28 Sultana N, Choudhary M I, Khan A. Protein glycation inhibitory activities of Lawsonia inermis and its active principles.  J Enzyme Inhib Med Chem. 2009;  24 257-261
    CrossrefPubMedGoogle Scholar
  • 29 Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice.  J Nutr. 2001;  131 235-241
    PubMedGoogle Scholar
  • 30 Kale A, Gawande S, Kotwal S, Netke S, Roomi W, Ivanov V, Niedzwiecki A, Rath M. Studies on the effects of oral administration of nutrient mixture, quercetin and red onions on the bioavailability of epigallocatechin gallate from green tea extract.  Phytother Res. 2009;  24 (Suppl. 1) S48-S55
    CrossrefPubMedGoogle Scholar
  • 31 Franke A A, Ashburn L A, Kakazu K, Suzuki S, Wilkens L R, Halm B M. Apparent bioavailability of isoflavones after intake of liquid and solid soya foods.  Br J Nutr. 2009;  102 1203-1210
    CrossrefPubMedGoogle Scholar
  • 32 Wautier M P, Massin P, Guillausseau P J, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier J L. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.  Diabetes Metab. 2003;  29 44-52
    CrossrefPubMedGoogle Scholar
  • 33 Fernandez M T, Mira M L, Florencio M H, Jennings K R. Iron and copper chelation by flavonoids: an electrospray mass spectrometry study.  J Inorg Biochem. 2002;  92 105-111
    CrossrefPubMedGoogle Scholar
  • 34 Kim D O, Lee C Y. Comprehensive study on vitamin C equivalent antioxidant capacity (VCEAC) of various polyphenolics in scavenging a free radical and its structural relationship.  Crit Rev Food Sci Nutr. 2004;  44 253-273
    CrossrefPubMedGoogle Scholar
  • 35 Urios P, Grigorova-Borsos A M, Sternberg M. Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure.  Eur J Nutr. 2007;  46 139-146
    CrossrefPubMedGoogle Scholar
  • 36 Baderschneider B, Winterhalter P. Isolation and characterization of novel benzoates, cinnamates, flavonoids, and lignans from Riesling wine and screening for antioxidant activity.  J Agric Food Chem. 2001;  49 2788-2798
    CrossrefPubMedGoogle Scholar
  • 37 Matsuda H, Wang T, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities.  Bioorg Med Chem. 2003;  11 5317-5323
    CrossrefPubMedGoogle Scholar
  • 38 Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes.  Pathol Biol (Paris). 2006;  54 405-419
    CrossrefPubMedGoogle Scholar
  • 39 Ferreira M L, Lang G C. Indigenous peoples and diabetes: community empowerment and wellness. Durham, North Carolina; Carolina Academic Press 2006: 549
    PubMedGoogle Scholar

Dr. John T. Arnason

Department of Biology
Centre for Research in Biopharmaceuticals and Biotechnology
University of Ottawa

30 Marie Curie

Ottawa, Ontario

Canada K1N 6N5

Phone: + 16 1 35 62 52 62

Fax: + 16 1 35 62 57 65

Email: John.Arnason@uOttawa.ca

      >